Clinical Trials Logo

MMR on 12 Month clinical trials

View clinical trials related to MMR on 12 Month.

Filter by:
  • None
  • Page 1

NCT ID: NCT05341050 Recruiting - MMR on 12 Month Clinical Trials

A Study on the Withdrawal of Second-generation Tyrosine Kinase Inhibitors After Dose Reduction in Patients With CML

Start date: April 1, 2022
Phase:
Study type: Observational

patients with Ph+ CML-CP who have been treated with second-generation TKIs (nilotinib, dasatinib) for at least 3 years and maintains MMR for at least 2 years, continue to be treated with halved dose for 12 months, and then stop for 12 months.

NCT ID: NCT04143087 Recruiting - MMR on 12 Month Clinical Trials

Withdrawal or Reduction TKIs in CML-CP

Start date: October 23, 2019
Phase:
Study type: Observational

Compare MMR on 12 month treated with half TKIs(including imatinib, dasatinib, and nilotinib) or TKIs withdrawal.